Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CAM-101
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Aventacell Biomedical
Deal Size : $3.0 million
Deal Type : Financing
Cambium Bio Successfully Closes A$3.0M Financing Round
Details : The proceeds will primarily support the advancement of CAM-101 Elate Ocular through its registration-enabling Phase 3 clinical trials for dry eye disease.
Brand Name : CAM-101
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 03, 2024
Lead Product(s) : CAM-101
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Aventacell Biomedical
Deal Size : $3.0 million
Deal Type : Financing
LOOKING FOR A SUPPLIER?